← Back to Screener
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Price$10.62
Favorite Metrics
Price vs S&P 500 (26W)-40.60%
Price vs S&P 500 (4W)13.65%
Market Capitalization$188.36M
All Metrics
Book Value / Share (Quarterly)$8.38
P/TBV (Annual)0.58x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.66
Price vs S&P 500 (YTD)25.96%
Net Profit Margin (TTM)-2838.71%
EPS (TTM)$-5.98
10-Day Avg Trading Volume0.25M
EPS Excl Extra (TTM)$-5.98
EPS (Annual)$-3.64
ROI (Annual)-28.08%
Net Profit Margin (5Y Avg)-2138.37%
Cash / Share (Quarterly)$9.27
ROA (Last FY)-25.66%
EBITD / Share (TTM)$-6.30
ROE (5Y Avg)-324.10%
Operating Margin (TTM)-4309.68%
Cash Flow / Share (Annual)$-3.66
P/B Ratio1.28x
P/B Ratio (Quarterly)0.97x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)103.14x
Net Interest Coverage (TTM)-14.44x
ROA (TTM)-57.88%
EPS Incl Extra (Annual)$-3.64
Current Ratio (Annual)8.07x
Quick Ratio (Quarterly)7.92x
3-Month Avg Trading Volume0.26M
52-Week Price Return78.89%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.07
P/S Ratio (Annual)214.05x
Asset Turnover (Annual)0.01x
52-Week High$20.56
Operating Margin (5Y Avg)-2440.93%
EPS Excl Extra (Annual)$-3.64
CapEx CAGR (5Y)-57.07%
Tangible BV CAGR (5Y)-10.60%
26-Week Price Return-31.85%
Quick Ratio (Annual)7.92x
13-Week Price Return28.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.07x
Enterprise Value$159.869
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)24.74%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5186.36%
Cash / Share (Annual)$9.27
3-Month Return Std Dev73.52%
Net Income / Employee (TTM)$-2
ROE (Last FY)-28.08%
Net Interest Coverage (Annual)-12.93x
EPS Basic Excl Extra (Annual)$-3.64
Receivables Turnover (TTM)1.11x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.98
ROI (TTM)-65.76%
P/S Ratio (TTM)121.52x
Pretax Margin (5Y Avg)-2138.37%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.91
Price vs S&P 500 (52W)43.79%
Year-to-Date Return30.10%
5-Day Price Return4.03%
EPS Normalized (Annual)$-3.64
ROA (5Y Avg)-79.97%
Net Profit Margin (Annual)-5186.36%
Month-to-Date Return12.78%
Cash Flow / Share (TTM)$-10.98
EBITD / Share (Annual)$-3.58
Operating Margin (Annual)-6362.50%
LT Debt / Equity (Annual)0.48x
ROI (5Y Avg)-271.09%
LT Debt / Equity (Quarterly)2.67x
EPS Basic Excl Extra (TTM)$-5.98
P/TBV (Quarterly)61.73x
P/B Ratio (Annual)0.97x
Pretax Margin (TTM)-2838.71%
Book Value / Share (Annual)$8.38
Price vs S&P 500 (13W)25.34%
Beta2.81x
Revenue / Share (TTM)$0.00
ROE (TTM)-65.76%
52-Week Low$5.75
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRBPCorbus Pharmaceuticals Holdings, Inc. | 121.52x | — | — | — | $10.62 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Corbus Pharmaceuticals is a biopharmaceutical company developing precision therapeutics for oncology and metabolic disorders. Its pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4 in cancer; CRB-601, an anti-integrin antibody designed to block TGF activation; and CRB-913, a CB1 receptor inverse agonist for obesity. These programs target validated biological pathways to address serious diseases.